yivoximab

Yivoximab (CDX-527) is a recombinant human IgG1 bispecific monoclonal antibody designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and Cluster of Differentiation 27 (CD27). Developed by Celldex Therapeutics, it utilizes a dual mechanism of action that combines checkpoint inhibition with immune co-stimulation. By blocking the PD-1/PD-L1 inhibitory pathway, yivoximab relieves immune suppression within the tumor microenvironment, while its CD27 agonist activity provides a potent co-stimulatory signal to T cells. This synergistic approach is intended to enhance anti-tumor immune responses more effectively than monotherapy targeting either pathway. The drug is primarily being investigated for the treatment of advanced or metastatic solid tumors that have failed standard therapies.

Other names

anti-PD-L1/CD27 bispecific antibody